Looking forward to seeing the results for cabo/ipi/nivo.
RT @DrChoueiri: 9/ Promising efficacy of cabozantinib/nivolumab in the treatment of papillary, unclassified and translocation-associated #R…
RT @DrChoueiri: 9/ Promising efficacy of cabozantinib/nivolumab in the treatment of papillary, unclassified and translocation-associated #R…
RT @DrChoueiri: 9/ Promising efficacy of cabozantinib/nivolumab in the treatment of papillary, unclassified and translocation-associated #R…
RT @DrChoueiri: 9/ Promising efficacy of cabozantinib/nivolumab in the treatment of papillary, unclassified and translocation-associated #R…
RT @DrChoueiri: 9/ Promising efficacy of cabozantinib/nivolumab in the treatment of papillary, unclassified and translocation-associated #R…
RT @DrChoueiri: 9/ Promising efficacy of cabozantinib/nivolumab in the treatment of papillary, unclassified and translocation-associated #R…
RT @DrChoueiri: 9/ Promising efficacy of cabozantinib/nivolumab in the treatment of papillary, unclassified and translocation-associated #R…
RT @DrChoueiri: 9/ Promising efficacy of cabozantinib/nivolumab in the treatment of papillary, unclassified and translocation-associated #R…
9/ Promising efficacy of cabozantinib/nivolumab in the treatment of papillary, unclassified and translocation-associated #RCC with a 47.5% ORR (median PFS 12.5 mos and OS 28 mos). Limited response in chromophobe RCC. @ChungHanLee3 @motzermd @JCO_ASCO http
RT @MSK_DeptOfMed: DoM's @ChungHanLee3 recently published results from a phase 2 trial in @JCO_ASCO that showed cabozantinib/nivolumab was…
RT @dralvaropinto: Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlate…
RT @dralvaropinto: Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlate…
RT @dralvaropinto: Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlate…
RT @dralvaropinto: Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlate…
RT @dralvaropinto: Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlate…
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates https://t.co/MXUtFp8mpb
RT @MSK_DeptOfMed: DoM's @ChungHanLee3 recently published results from a phase 2 trial in @JCO_ASCO that showed cabozantinib/nivolumab was…
RT @MSK_DeptOfMed: DoM's @ChungHanLee3 recently published results from a phase 2 trial in @JCO_ASCO that showed cabozantinib/nivolumab was…
RT @MSK_DeptOfMed: DoM's @ChungHanLee3 recently published results from a phase 2 trial in @JCO_ASCO that showed cabozantinib/nivolumab was…
RT @MSK_DeptOfMed: DoM's @ChungHanLee3 recently published results from a phase 2 trial in @JCO_ASCO that showed cabozantinib/nivolumab was…
DoM's @ChungHanLee3 recently published results from a phase 2 trial in @JCO_ASCO that showed cabozantinib/nivolumab was effective in the treatment of papillary, unclassified, or translocation-associated renal cell carcinoma. Read the study ⬇️ #Cancer 📖: h
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @DrScottHaake: For comparison, Checkmate9ER observed a 56% objective response rate in untreated clear cell RCC population receiving cabo…
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates: promising efficacy particularly those with prominent papillary features https://t.co/oVpYJnBPxk
RT @DrScottHaake: For comparison, Checkmate9ER observed a 56% objective response rate in untreated clear cell RCC population receiving cabo…
RT @DrScottHaake: For comparison, Checkmate9ER observed a 56% objective response rate in untreated clear cell RCC population receiving cabo…
RT @DrScottHaake: For comparison, Checkmate9ER observed a 56% objective response rate in untreated clear cell RCC population receiving cabo…
For comparison, Checkmate9ER observed a 56% objective response rate in untreated clear cell RCC population receiving cabo/nivo. This non-clear cell #kidneycancer data from @chunghanlee3 & @motzerMD & colleagues in @JCO_ASCO an important contributio
Important work evaluating cabo/nivo in non-clear cell RCC from @MSKCancerCenter #kidneycancer team. A response rate of 47% in the papillary/unclassified/translocation RCC cohort seems pretty robust, especially when considering ~1/3 were pretreated. https:
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
Another option for non-clear cell RCC #mRCC
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
Totally agree! Overdue.
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
ORR for cohort 1 (n = 40) predominantly papillary ,was 47.5% with mPFS of 12.5 mo and mOS of 28 months . for the first time these results came close to clear cell RCC. I would like to find something encouraging for the chromophobe rcc too. #kidneycancer,@N
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
RT @ChungHanLee3: Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN…
Excited to see that nivolumab + cabozantinib has been incorporated into the NCCN guidelines for non-clear cell RCC. @NCCN @bmsnews @ExelixisInc @JCO_ASCO @motzermd @MVossMD @pearldaily https://t.co/z73SXB1y2u https://t.co/DlLSUWQdta
RT @ChungHanLee3: Retrospective study showing benefit of TKI/ICI in FH-deficient RCC in @EUplatinum https://t.co/tx4r3X8riF Would love to s…
Retrospective study showing benefit of TKI/ICI in FH-deficient RCC in @EUplatinum https://t.co/tx4r3X8riF Would love to see a larger prospective study to validate our initial finding that cabo/nivo had 5/6 objective responses for these patients https://t.
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates https://t.co/55wF71QPdz
RT @ChungHanLee3: Hoping that this data will help more patients get access to the combination. Looking forward to seeing how it might impac…
RT @ChungHanLee3: Hoping that this data will help more patients get access to the combination. Looking forward to seeing how it might impac…
RT @ChungHanLee3: Hoping that this data will help more patients get access to the combination. Looking forward to seeing how it might impac…
RT @JCO_ASCO: Cabozantinib + Nivolumab in non-clear cell #RenalCellCarcinoma 🗒️ Phase II trial 🧑🏽🤝🧑🏽 n=47 🙌 Response rate 48% 🤩 Response…
RT @JCO_ASCO: Cabozantinib + Nivolumab in non-clear cell #RenalCellCarcinoma 🗒️ Phase II trial 🧑🏽🤝🧑🏽 n=47 🙌 Response rate 48% 🤩 Response…
RT @JCO_ASCO: Cabozantinib + Nivolumab in non-clear cell #RenalCellCarcinoma 🗒️ Phase II trial 🧑🏽🤝🧑🏽 n=47 🙌 Response rate 48% 🤩 Response…
RT @JCO_ASCO: Cabozantinib + Nivolumab in non-clear cell #RenalCellCarcinoma 🗒️ Phase II trial 🧑🏽🤝🧑🏽 n=47 🙌 Response rate 48% 🤩 Response…
RT @JCO_ASCO: Cabozantinib + Nivolumab in non-clear cell #RenalCellCarcinoma 🗒️ Phase II trial 🧑🏽🤝🧑🏽 n=47 🙌 Response rate 48% 🤩 Response…
RT @urbano_anido: Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates…
RT @urbano_anido: Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates…
@PauRomvil
RT @JCO_ASCO: Cabozantinib + Nivolumab in non-clear cell #RenalCellCarcinoma 🗒️ Phase II trial 🧑🏽🤝🧑🏽 n=47 🙌 Response rate 48% 🤩 Response…
RT @JCO_ASCO: Cabozantinib + Nivolumab in non-clear cell #RenalCellCarcinoma 🗒️ Phase II trial 🧑🏽🤝🧑🏽 n=47 🙌 Response rate 48% 🤩 Response…
RT @JCO_ASCO: Cabozantinib + Nivolumab in non-clear cell #RenalCellCarcinoma 🗒️ Phase II trial 🧑🏽🤝🧑🏽 n=47 🙌 Response rate 48% 🤩 Response…
RT @ChungHanLee3: Hoping that this data will help more patients get access to the combination. Looking forward to seeing how it might impac…
RT @ChungHanLee3: Hoping that this data will help more patients get access to the combination. Looking forward to seeing how it might impac…
RT @ChungHanLee3: Hoping that this data will help more patients get access to the combination. Looking forward to seeing how it might impac…
RT @ChungHanLee3: Hoping that this data will help more patients get access to the combination. Looking forward to seeing how it might impac…
RT @ChungHanLee3: Hoping that this data will help more patients get access to the combination. Looking forward to seeing how it might impac…
RT @ChungHanLee3: Hoping that this data will help more patients get access to the combination. Looking forward to seeing how it might impac…
RT @ChungHanLee3: Hoping that this data will help more patients get access to the combination. Looking forward to seeing how it might impac…
RT @ChungHanLee3: Hoping that this data will help more patients get access to the combination. Looking forward to seeing how it might impac…
RT @urbano_anido: Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates…
RT @JCO_ASCO: Cabozantinib + Nivolumab in non-clear cell #RenalCellCarcinoma 🗒️ Phase II trial 🧑🏽🤝🧑🏽 n=47 🙌 Response rate 48% 🤩 Response…
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates | Journal of Clinical Oncology https://t.co/8yMJf7MovH
RT @ChungHanLee3: Hoping that this data will help more patients get access to the combination. Looking forward to seeing how it might impac…
RT @JCO_ASCO: Cabozantinib + Nivolumab in non-clear cell #RenalCellCarcinoma 🗒️ Phase II trial 🧑🏽🤝🧑🏽 n=47 🙌 Response rate 48% 🤩 Response…
RT @JCO_ASCO: Cabozantinib + Nivolumab in non-clear cell #RenalCellCarcinoma 🗒️ Phase II trial 🧑🏽🤝🧑🏽 n=47 🙌 Response rate 48% 🤩 Response…
RT @JCO_ASCO: Cabozantinib + Nivolumab in non-clear cell #RenalCellCarcinoma 🗒️ Phase II trial 🧑🏽🤝🧑🏽 n=47 🙌 Response rate 48% 🤩 Response…
RT @JCO_ASCO: Cabozantinib + Nivolumab in non-clear cell #RenalCellCarcinoma 🗒️ Phase II trial 🧑🏽🤝🧑🏽 n=47 🙌 Response rate 48% 🤩 Response…
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates: particularly those with prominent papillary features, treatment effects were limited in chromophobe. https://t.co/LuEB988Nuq
RT @JCO_ASCO: Cabozantinib + Nivolumab in non-clear cell #RenalCellCarcinoma 🗒️ Phase II trial 🧑🏽🤝🧑🏽 n=47 🙌 Response rate 48% 🤩 Response…
Hoping that this data will help more patients get access to the combination. Looking forward to seeing how it might impact the treatment guidelines.
RT @JCO_ASCO: Cabozantinib + Nivolumab in non-clear cell #RenalCellCarcinoma 🗒️ Phase II trial 🧑🏽🤝🧑🏽 n=47 🙌 Response rate 48% 🤩 Response…